Dr. Richard Dolinar presented at the Center for Business Intelligence 8th Annual Biosimilars Summit in Washington, D.C. on March 5.

Dr. Dolinar’s presentation, “Assessing Global Standards for Biologic Medicines” stressed the need for a global regulatory environment that ensures patient safety, especially in regards to approval processes, biosimilar naming and substitution.